✓ Η πληρωμή με πιστωτική κάρτα αποκαταστάθηκε — ασφαλής ολοκλήρωση αγοράς μέσω Privacy Shield

Soranib

Soranib (Sorafenib 200 mg) — Cipla multikinase TKI inhibiting VEGFR, PDGFR, RAF for HCC, RCC, differentiated thyroid carcinoma.

Ιατρικά ελεγμένο από Morgan Ellis — Ερευνητής Φαρμακευτικής · 8 χρόνια εμπειρία  · Τελευταία αναθεώρηση: Μάιος 2026

Κρυπτογραφημένη αγορά
Η πληρωμή με κρυπτονομίσματα κοστίζει 10% λιγότερο
Διακριτική παγκόσμια αποστολή
1,400+ πελάτες · 50+ χώρες

Αυτό το προϊόν είναι προσωρινά εξαντλημένο και μη διαθέσιμο.

Γρήγορη απάντηση

Soranib — Sorafenib 200 mg (Cipla Inc). Multikinase inhibitor for hepatocellular, renal cell, and differentiated thyroid carcinoma.

Αυτό που λαμβάνετε με την MedsBase:

  • πιστοποιημένο από τη WHO-GMP κατασκευαστή
  • Discreet plain-envelope packaging
  • Παγκόσμια αποστολή
  • Rated by 1,400+ customers (read reviews)

📦 Reshipment Assurance: if your order has not arrived 20 business days after dispatch, we reship it at no extra cost. Read the policy.

Γιατί να παραγγείλετε από τη MedsBase

Soranib ships from a WHO-GMP certified manufacturer in plain packaging, billed through a regulated payment processor (the statement descriptor reads a regulated card-payment processor — never MedsBase or any medication name). Every order carries our 20-business-day Reshipment Assurance.

⚠️ Specialist-supervised cancer therapy — this medication is started, monitored, and stopped by an oncologist or haematologist. Dosing depends on tumour type, stage, body surface area, organ function, and concomitant therapy. Self-treatment is not appropriate; the information below is educational and supports informed conversations with your specialist.

TKI class principles
Tyrosine kinase inhibitors are oral targeted therapies. They require specialist initiation, ongoing therapeutic drug monitoring (where available), and management of class-specific toxicities. Adherence is critical — missed doses risk treatment failure. Most TKIs are CYP3A4 substrates with major drug interactions.

Συχνές Ερωτήσεις

What is a TKI?

Tyrosine kinase inhibitors block specific signalling pathways driving cancer cell growth. Each TKI is selective for different targets (EGFR for gefitinib/erlotinib; multikinase for sorafenib/sunitinib; BCR-ABL for nilotinib/imatinib; BTK for ibrutinib; JAK for ruxolitinib; CDK4/6 for palbociclib).

Side effects?

Class signature: rash (often correlates with response in EGFR inhibitors), diarrhoea, fatigue, hand-foot skin reaction, hypertension (multikinase), hepatotoxicity, QT prolongation. Each TKI has a specific profile.

Drug interactions?

Most TKIs are CYP3A4 substrates. Strong inhibitors (azoles, macrolides, ritonavir, grapefruit) raise levels and toxicity; strong inducers (rifampicin, phenytoin, carbamazepine, St John’s wort) drop levels and risk treatment failure.

Take with food?

Some TKIs (lapatinib, erlotinib) on empty stomach (food increases bioavailability variably). Others (gefitinib, sorafenib) with or without food. Specific instruction depends on the molecule — confirm with prescribing oncologist.

What about response monitoring?

Imaging (CT/MRI/PET) every 2-3 months early; tumour markers if applicable. Treatment continues while benefit; switch on progression or unacceptable toxicity.

Resistance?

TKI resistance develops over time (typically 9-18 months in solid tumours). Mechanisms: target mutations (T790M for EGFR, T315I for BCR-ABL), alternate pathway activation, target overexpression. Next-generation TKIs (osimertinib, ponatinib) overcome specific resistance mutations.

Τι γίνεται αν χάσω μια δόση;

Take when you remember if same day if >6 hours from next dose. Otherwise skip — do not double up. Specific instructions vary by drug; confirm with your oncology team.

Pregnancy?

All TKIs are teratogenic — effective contraception during and for at least 4-6 months after for both partners.

Cardiac monitoring?

Multikinase TKIs (sorafenib, sunitinib): BP monitoring, ECG (QT), echocardiogram in selected cases. BCR-ABL TKIs (nilotinib): mandatory ECG at baseline and follow-up — QT prolongation.

Cost-effectiveness?

Generic TKIs are widely manufactured under voluntary licences in India and other jurisdictions. Indian generic prices are dramatically lower than branded equivalents. Quality and bioequivalence are well-documented.

Other Cancer Medications

  • Xeloda — capecitabine 500 mg — oral 5-FU prodrug for breast/colorectal/gastric cancers
  • Altraz — anastrozole 1 mg — aromatase inhibitor for post-menopausal breast cancer
  • Xbira — abiraterone 250 mg — CYP17 inhibitor for metastatic prostate cancer
  • Zoldria — zoledronic acid IV — for bone metastases and hypercalcaemia
  • Actorise — darbepoetin alfa — for chemotherapy-induced anaemia
Ιατρική Αποποίηση Ευθυνών: Cancer therapy is highly individualised. Specific drug, dose, schedule, monitoring, and supportive care must be determined by a qualified oncologist or haematologist based on tumour biology, staging, comorbidities, and goals of care. This information is educational; it does not substitute for professional medical advice.

More options in Anti Cancer Medication

Ταξινομημένα σύμφωνα με τον όγκο παραγγελιών στο MedsBase — τι επιλέγουν άλλοι πελάτες σε αυτήν την κατηγορία.

Ισχύς

200 mg

Ποσότητα

120 Tablet/s, 240 Tablet/s

Φαρμακευτική Μορφή

Δισκία

Κατασκευαστής

Cipla Inc

Θεραπεία

Liver cancer, Kidney cancer, Thyroid cancer

Γενόσημη μάρκα

Sorafenib

Κριτικές

Δεν υπάρχουν ακόμη κριτικές

Προσθήκη κριτικής
Soranib Soranib
Αξιολόγηση*
0/5
* Η αξιολόγηση είναι υποχρεωτική
* Η απάντηση είναι υποχρεωτική
Η κριτική σας
* Η κριτική είναι υποχρεωτική
Όνομα
* Απαιτείται όνομα
Προσθέστε φωτογραφίες ή βίντεο στην κριτική σας

Ερωτήσεις & Απαντήσεις

Κάντε μια ερώτηση
Soranib Soranib
Η ερώτησή σας
* Απαιτείται ερώτηση
Όνομα
* Απαιτείται όνομα
Δεν υπάρχουν ακόμα ερωτήσεις